About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
At Diagnostic Nanotools, we work to ameliorate the diagnosis of diseases. On the one hand, we produce rapid assays and electrochemical biosensors, with a special emphasis on point-of-care diagnosis of infectious diseases.
In this context, we develop single-step immunoassays, classical biosensors (in which a sensor is modified with bioreceptors for the specific detection of the analyte of interest) and magneto-biosensors (in which the assay is performed on magnetic particles). We explore the implementation of nanomaterials to obtain improved transducers and as signal amplifiers to generate faster and more sensitive biosensors. We also seek to automate the tests using extremely simple and economical paper microfluidics. On the other hand, we are developing "synthrocytes," a synthetic reagent that could replace animal erythrocytes in the hemagglutination assays used currently for the global surveillance of influenza viruses and in the control of vaccine production.
A VHIR team travels to Angola to test, under real-world conditions, an innovative device designed for mass diagnosis in resource-limited settings.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
